Successful Site Transfer Of Tablet Production From Ex-U.S. To Bend Bioscience Georgia Site

In response to a comprehensive risk assessment identifying vulnerabilities in its supply chain, including exposure to natural disasters and global shipping constraints, a pharmaceutical company partnered with Bend Bioscience to strengthen the resilience of its immediate-release tablet product manufacturing. The company’s original manufacturing facility, located outside the U.S. in a region prone to natural disasters, posed a significant risk of prolonged supply disruption.

To mitigate this, the company chose to relocate production to the U.S. — its largest market — to reduce lead times, lower shipping costs, avoid import delays, and minimize exposure to tariff enforcement. Additionally, establishing a second source of supply by filing for regulatory approval in multiple markets ensured greater supply chain redundancy. After evaluating several U.S.-based CDMOs, the company selected Bend Bioscience’s Georgia facility, where a dedicated team successfully managed the technology transfer and supported the FDA site approval process.

Download the full case study to learn how strategic relocation can fortify pharmaceutical supply chains.